Literature DB >> 21686756

Metastatic osteosarcoma to the liver and the kidney: a case report and review of the literature.

Wen-Xi Yu1, Yang Yao.   

Abstract

Improvements in multimodal treatment for osteosarcoma, especially in the use of adjuvant chemotherapy, have increased event-free and overall survival. Meanwhile, the prolonged survival of patients has permitted the appearance of new, significant, extrapulmonary targets for metastasis. Here we report a middle-aged adult with osteosarcoma who developed hepatic and renal metastases 4 months after the diagnosis of osteosarcoma. Chemotherapy and radiofrequency ablation were performed. CT scan has shown that the metastatic lesion has stabilised in the liver and kidney in the latest follow-up. This suggests that early multimodal treatment may improve both the survival rate and the quality of life of osteosarcoma patients with extrapulmonary metastases.

Entities:  

Year:  2009        PMID: 21686756      PMCID: PMC3029436          DOI: 10.1136/bcr.07.2008.0536

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  Bilateral renal metastases from osteosarcoma: A case report and review of the literature.

Authors:  Luís Henrique Toshihiro Sakamoto; Wellington Mendes; Marcela Pecora; Rodrigo Guimarães Andrade; Maria Dirlei Ferreira Begnani; Beatriz de Camargo
Journal:  J Pediatr Hematol Oncol       Date:  2006-09       Impact factor: 1.289

2.  Case report: calcified liver metastases from osteosarcoma.

Authors:  R S Shapiro; D S Mendelson; K I Norton; C Janus; E S Gendal; G Hermann
Journal:  J Comput Tomogr       Date:  1988-07

3.  18 F uptake within metastatic osteosarcoma of the liver. A case report.

Authors:  R E O'Mara; A Brettner; J A Danigelis; L V Gould
Journal:  Radiology       Date:  1971-07       Impact factor: 11.105

4.  Metastatic extraosseous osteosarcoma to the liver: a case demonstrated by 85 Sr and 99m Tc-colloid scanning.

Authors:  M K Dalinka; A E Fiveash; J K Aston
Journal:  J Nucl Med       Date:  1971-11       Impact factor: 10.057

5.  Metastatic osteosarcoma to the liver after treatment for synovial sarcoma: a case report.

Authors:  N C Daw; S C Kaste; D A Hill; L E Kun; C B Pratt
Journal:  Pediatr Hematol Oncol       Date:  2001-03       Impact factor: 1.969

6.  Lace-like enhancement pattern of osteosarcoma of rib and liver metastasis in CT scans.

Authors:  H H Chan; J K Chan; W M Ng; T W Shek; F L Chan
Journal:  Australas Radiol       Date:  2001-08

7.  Brain metastases in osteosarcoma. Report of a long-term survivor and review of the St. Jude Children's Research Hospital experience.

Authors:  N M Marina; C B Pratt; S J Shema; T Brooks; B Rao; W H Meyer
Journal:  Cancer       Date:  1993-06-01       Impact factor: 6.860

8.  Changing metastatic patterns of a transplantable rat osteosarcoma.

Authors:  F Wingen; E Weber
Journal:  Clin Exp Metastasis       Date:  1987 Jan-Mar       Impact factor: 5.150

9.  Changing metastatic patterns of osteosarcoma.

Authors:  A E Giuliano; S Feig; F R Eilber
Journal:  Cancer       Date:  1984-11-15       Impact factor: 6.860

10.  The metastatic patterns of osteosarcoma.

Authors:  G M Jeffree; C H Price; H A Sissons
Journal:  Br J Cancer       Date:  1975-07       Impact factor: 7.640

  10 in total
  2 in total

1.  Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma.

Authors:  Olaf Beck; Claudia Paret; Alexandra Russo; Jürgen Burhenne; Margaux Fresnais; Kevin Steimel; Larissa Seidmann; Daniel-Christoph Wagner; Nadine Vewinger; Nadine Lehmann; Maximilian Sprang; Nora Backes; Lea Roth; Marie Astrid Neu; Arthur Wingerter; Nicole Henninger; Khalifa El Malki; Henrike Otto; Francesca Alt; Alexander Desuki; Thomas Kindler; Joerg Faber
Journal:  Cancers (Basel)       Date:  2020-03-26       Impact factor: 6.639

2.  The miR-193a-5p/NCX2/AKT axis promotes invasion and metastasis of osteosarcoma.

Authors:  Ruiqi Chen; Yichong Ning; Guirong Zeng; Hao Zhou; Lin Zhou; Pei Xiao; Zhihong Li; Jianlin Zhou
Journal:  J Cancer       Date:  2021-08-08       Impact factor: 4.207

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.